Novo Nordisk signed a deal worth up to $1.4 billion with Orbis Medicines on September 17, 2026, to use AI-designed oral macrocycle drugs for cardiometabolic disease, aiming to replace injectable treatments with pills.
Insilico Medicine published an open-source AI toolkit for aging research in Cell on September 17, 2026, with Liquid AI, the Buck Institute, and Harvard Medical School, nominating 328 candidate longevity gene targets.
Meta's new Ray-Ban Meta Gen 3 AI glasses, unveiled September 23, 2026, have become a genuine lifeline for many blind and low-vision users, but critics argue the company is leaning on disabled users' enthusiasm while dodging accessibility accountability.
As wildfire smoke triggered fresh air quality advisories across the Bay Area in September 2026, researchers are testing AI models that combine wearable health data with pollution readings to predict how smoke affects each person differently.
A 2026 ADA survey found 43.3% of US dentists now use AI, mostly to catch cavities in X-rays before they're visible to the eye, while new consumer apps let people scan their own teeth at home, raising fresh questions about overtreatment.
Connecticut announced AI claim-denial oversight rules on September 16, 2026, but they only cover the roughly 220,000 residents on state employee health plans, leaving millions on private insurance without similar protection.
A September 2, 2026 commentary argues the next psychiatric diagnostic manual must reckon with how recommendation algorithms shape eating disorders, as researchers race to build AI tools that detect early warning signs on social media.
Scripps Research published ECG-CLIP on September 1, 2026, an AI foundation model that detects heart disease from ECGs using 91% less labeled training data than existing tools, potentially speeding up detection of rarer cardiac conditions.
A major September 28, 2026 review shows how AI is combining gut microbiome, genetic, and metabolic data to generate truly individualized diet advice, though researchers caution the science hasn't yet caught up to consumer marketing claims.
Dexcom is adding AI-driven coaching features to its over-the-counter Stelo glucose sensor and expanding internationally, pushing continuous glucose monitoring further into mainstream wellness even as evidence for non-diabetics stays thin.